Cerus Corporation (CERS) is a leading biomedical products company dedicated to enhancing blood safety through its innovative INTERCEPT Blood System, which effectively inactivates pathogens in blood components. Based in Concord, California, Cerus leverages cutting-edge technology to address critical needs in transfusion medicine, offering solutions that are vital for patient safety. With a growing portfolio and a commitment to advancing blood safety protocols globally, Cerus is well-positioned within the healthcare sector, catering to the increasing demand for safe blood products.